IP Library Granted Patent US 9,289,539
Granted Patent B2
US 9,289,539 · App. 14/683,612 · Granted Mar 22, 2016

Drug releasing coatings for medical devices

Inventor: Lixiao Wang (Medina, MN)
Assignee: Lutonix, Inc.
A61L31/16A61K31/337A61K31/436A61L29/08A61L29/085A61L29/16A61L31/08A61L2300/416A61L2300/428A61L2300/606A61L2300/608A61L2300/802A61M25/10A61M2025/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,289,539
App. No.
14/683,612
Granted
Mar 22, 2016
Kind
B2
Abstract

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.

Claims (18)

1. A medical device for delivering a therapeutic agent to a tissue, the medical device comprising:

a coating layer overlying an exterior surface of the medical device, wherein:

the coating layer consisting essentially of a therapeutic agent and at least one additive;

the therapeutic agent is a water-insoluble drug chosen from paclitaxel, rapamycin, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, and combinations thereof;

the at least one additive is selected from the group consisting of urea, acetamide, lactic acid amide, aminoacid amide, acetaminophen, uric acid, polyurea, urethane, urea derivatives, niacinamide, N-methylacetamide, N,N-dimethylacetamide, sulfacetamide sodium, versetamide, lauric diethanolamide, lauric myristic diethanolamide, N,N-Bis(2-hydroxyethyl stearamide), cocamide EA, and cocamide DEA.

2. The medical device of claim 1 , wherein the at least one additive is selected from the group consisting of urea, acetamide, aminoacid amide, uric acid, polyurea, N-methylacetamide, N,N-dimethylacetamide, sulfacetamide sodium, versetamide, lauric diethanolamide, lauric myristic diethanolamide, N,N-Bis(2-hydroxyethyl stearamide), cocamide EA, and cocamide DEA.

3. The medical device of claim 1 , wherein the medical device is one of a balloon catheter, a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, a scoring balloon catheter, a laser catheter, or a stent graft.

4. The medical device of claim 1 , wherein the at least one additive is selected from the group consisting of urea, uric acid, polyurea, urethane, and urea derivatives.

5. The medical device of claim 1 , wherein the at least one additive comprises urea.

6. The medical device of claim 5 , wherein the medical device is a balloon catheter.

7. The medical device of claim 1 , wherein the therapeutic agent comprises paclitaxel and the at least one additive comprises urea.

8. The medical device of claim 1 , wherein the medical device is a balloon catheter, the therapeutic agent comprises paclitaxel, and the at least one additive comprises urea.

9. The medical device of claim 1 , wherein the medical device is a stent graft, the therapeutic agent comprises paclitaxel, and the at least one additive comprises urea.

10. The medical device of claim 1 , wherein the at least one additive does not react with the therapeutic agent during sterilization of the medical device.

11. The medical device of claim 1 , wherein the at least one additive does not react with the therapeutic agent during sterilization of the medical device in ethylene oxide.

12. The medical device of claim 1 , wherein the concentration of the therapeutic agent in the coating layer is from 1 μg/mm 2 to 20 μg/mm 2 .

13. The medical device of claim 1 , wherein the tissue includes tissue of one of coronary vasculature, peripheral vasculature, cerebral vasculature, esophagus, airways, sinus, trachea, colon, biliary tract, urinary tract, prostate, or brain passages.

14. The medical device of claim 1 , further comprising a top layer overlying the surface of the coating layer overlying the exterior surface of the medical device to reduce loss of therapeutic agent during transit through a body to the tissue.

Continuity (13)
Continuation 13846143 · Mar 18, 2013
Continuation 12731835 · Mar 25, 2010
Continuation In Part 12121986 · May 16, 2008
Continuation In Part 11942452 · Nov 19, 2007
Provisional Application 60860084 · Nov 20, 2006
Provisional Application 60880742 · Jan 17, 2007
Provisional Application 60897427 · Jan 25, 2007
Provisional Application 60903529 · Feb 26, 2007
Provisional Application 60904473 · Mar 2, 2007
Provisional Application 60926850 · Apr 30, 2007
Provisional Application 60981380 · Oct 19, 2007
Provisional Application 60981384 · Oct 19, 2007
Related Publication 20150209489A1 · Jul 30, 2015